ArticleJournal of medicinal chemistry2023
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.
Abstract read
In one paragraph
Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Disulfide bond formation between Cys22 and Cys44 in SARS-CoV-2 main protease.Bioorganic & medicinal chemistry letters · 2026Article
- High-Throughput Screening Identifies Covalent Inhibitors with Unique Chemistry and Binding Modes for SARS-CoV‑2 Main Protease.JACS Au · 2026Article
- Nicotine-Inspired, De Novo-Designed SARS-CoV-2 Main Protease Inhibitors Reveal Unique Chemistry for Covalently Conjugating Both Cysteine and Histidine Residues in the Catalytic Dyad.Journal of the American Chemical Society · 2026Article
- From nicotine to SARS-CoV-2 antivirals with potent in vivo efficacy and a broad anti-coronavirus spectrum.Nature communications · 2026Article
- Regioselective multicomponent synthesis of α-boryl ureas: discovery of a potent main protease inhibitor.Organic & biomolecular chemistry · 2026Article
- Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Sequential Optimization Approach Toward an Azapeptide-Based SARS-CoV-2 Main Protease Inhibitor.Archiv der Pharmazie · 2025Article
- Identification and Exploration of a Series of SARS-Cov‑2 MACS medicinal chemistry letters · 2025Article
- SARS-CoV-2 Main Protease Inhibitors That Leverage Unique Interactions with the Solvent Exposed S3 Site of the Enzyme.ACS medicinal chemistry letters · 2024Article
- Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.Antiviral research · 2024Article
- On the origins of SARS-CoV-2 main protease inhibitors.RSC medicinal chemistry · 2024Review
- Targeted degrader technologies as prospective SARS-CoV-2 therapies.Drug discovery today · 2024Review
- Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.Biomolecules · 2023Review
- Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir.ACS central science · 2023Article
Corrections and comments
- Update of
Authors and funding
18 authors.
Zhi Zachary GengDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.
Sandeep AtlaDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.
Namir ShaabaniSorrento Therapeutics, Inc. San Diego, California 92121, United States.
Veerabhadra VulupalaDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.
Kai S YangDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.ORCID 0000-0002-1890-4169
Yugendar R AlugubelliDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.
Kaustav KhatuaDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.
Peng-Hsun ChenDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.ORCID 0000-0001-9822-6398
Jing XiaoDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.
Lauren R BlankenshipDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.
Xinyu R MaDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.
Erol C VatanseverDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.
Chia-Chuan D ChoDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.
Yuying MaDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.
Robert AllenSorrento Therapeutics, Inc. San Diego, California 92121, United States.
Henry JiSorrento Therapeutics, Inc. San Diego, California 92121, United States.
Shiqing XuDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.ORCID 0000-0001-6260-9290
Wenshe Ray LiuDepartment of Chemistry, Texas A&M Drug Discovery Laboratory, Texas A&M University, College Station, Texas 77843, United States.ORCID 0000-0002-7078-6534
Funding
THEORETICAL STUDIES OF ENZYMATIC REACTIONSR01GM024492 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI WARSHEL, ARIEH · 1985 to 2017
$5.0MUse of the Noncanonical Amino Acid Mutagenesis Technique in Combination with Other Approaches to Study Functions of Posttranslational Lysine Modifications in ProteinsR35GM145351 · NIGMS · TEXAS A&M UNIVERSITY · PI Wenshe Ray Liu · 2022 to 2026
$2.6MDevelopment of fluorogenic and chemiluminogenic main protease substrates for cellular and in vivo imaging of SARS-CoV-2R21EB032983 · NIBIB · TEXAS A&M UNIVERSITY · PI LIU, WENSHE RAY · 2022 to 2023
$411kThe Development of Reversible Covalent PROTAC Technology as a New Anti-COVID-19 StrategyR21AI164088 · NIAID · TEXAS A&M UNIVERSITY · PI XU, SHIQING · 2021 to 2022
$406kNIAID NIH HHS R21 AI164088NIBIB NIH HHS R21 EB032983NIGMS NIH HHS R01 GM024492NIGMS NIH HHS R35 GM145351
Abstract
SARS-CoV-2, the COVID-19 pathogen, relies on its main protease (M
Indexed as
Coronavirus Protease InhibitorsCOVID-19AlkanesAntiviral AgentsAza CompoundsCarboxylic AcidsCoronavirus 3C ProteasesHumansMolecular Docking SimulationSARS-CoV-2Spiro Compounds3C-like proteinase, SARS-CoV-2AlkanesAntiviral AgentsAza CompoundsCarboxylic AcidsCoronavirus 3C ProteasesCoronavirus Protease InhibitorsMPI60nonaneSpiro Compounds
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.